In the News

Alterity Therapeutics Publishes Pre-Clinical Data for ATH434 in Multiple System Atrophy

By August 12, 2021 No Comments
In the News

Alterity Therapeutics Publishes Pre-Clinical Data for ATH434 in Multiple System Atrophy

By August 12, 2021 No Comments

Alterity Therapeutics Publishes Pre-Clinical Data for ATH434 in Multiple System Atrophy

There are currently no treatments available for multiple system atrophy (MSA), a rare and fatal neurodegenerative disorder caused by the accumulation of alpha-synuclein in the brain. MSA causes problems with movement, balance, and the control of some involuntary bodily functions such as blood pressure and bowel and bladder function. Last month, Alterity Therapeutics published promising results in Movement Disorders of ATH434 in a mouse model of the disease.

ATH434 is a small molecule that targets alpha-synuclein in MSA and Parkinson’s disease (PD). In the study, researchers demonstrated that it not only protected neurons from the damaging effects of alpha-synuclein, but that it also improved motor function—an important finding given that problems with movement are a significant source of disability in patients with MSA.

Alterity has completed a study of ATH434 in a trial of healthy volunteers and is on track to begin a Phase 2 trial in MSA later this year.

READ MORE

Alterity Therapeutics Publishes Pre-Clinical Data for ATH434 in Multiple System Atrophy

There are currently no treatments available for multiple system atrophy (MSA), a rare and fatal neurodegenerative disorder caused by the accumulation of alpha-synuclein in the brain. MSA causes problems with movement, balance, and the control of some involuntary bodily functions such as blood pressure and bowel and bladder function. Last month, Alterity Therapeutics published promising results in Movement Disorders of ATH434 in a mouse model of the disease.

ATH434 is a small molecule that targets alpha-synuclein in MSA and Parkinson’s disease (PD). In the study, researchers demonstrated that it not only protected neurons from the damaging effects of alpha-synuclein, but that it also improved motor function—an important finding given that problems with movement are a significant source of disability in patients with MSA.

Alterity has completed a study of ATH434 in a trial of healthy volunteers and is on track to begin a Phase 2 trial in MSA later this year.

READ MORE
CND Life Sciences

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.